Abstract
The prostate cancer cell lines PC3 and LNCaP have been shown to lack expression of the tumour suppressor gene MMAC1/PTEN, in contrast to the immortalized non-tumorigenic epithelial lines PNT1a and PNT2. We have measured the effects of reintroduction of wild type (wt) and mutant MMAC1 genes on to these genetic backgrounds, using gene constructs expressing either wt MMAC1 or various mutants deficient in the dual specificity phosphatase domain of the protein. Over-expression of wild type PTEN protein induced cell shrinkage and rounding, but did not result in increased levels of classical apoptosis. Permanently transfected lines containing the MMAC1 gene could only be obtained from the PNT cells, as PTEN expression resulted in rapid loss of both tumour lines. In contrast, mutation of the phosphatase domain resulted in partial attenuation of the phenotypic effects of MMAC1 after transient transfection, and also allowed the derivation of permanent tumour cell lines containing the mutated MMAC1 gene. The results suggest that re-expression of wt PTEN is incompatible with survival of human prostate cancer cells in vitro, and that the full biological activity of this common tumour suppressor requires functions additional to the established protein and lipid phosphatase activities in epithelial systems. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bergerheim USR, Kunimi K, Collins VP and Ekman P (1991) Deletion mapping of chromosome-8, chromosome-10, and chromosome-16 in human prostatic carcinoma. Genes Chromosom Cancer 3: 215–220
Berthon P, Cussenot O, Hopwood L, Le Duc A and Maitland NJ (1995) Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines. Int J Oncol 6: 333–343
Boström J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP and Reifenberger G (1998) Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29–33
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman Jg Jen J, Isaacs WB, Bova GS and Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997–5000
Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV and Bookstein R (1998) Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 58: 2331–2334
Cheney IW, Neuteboom STC, Vaillancourt MT, Ramachandra M and Bookstein R (1999) Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27kipl into cyclin E/CDK2 complexes. Cancer Res 59: 2318–2323
Cussenot O, Berthon P, Faille A, Berger R, Mowszowicz I, Teillac P, LeDuc A and Calvo F (1991) Immortalization of human adult normal prostatic epithelial cells by liposomes containing SV40. J Urol 143: 881–886
Davies MA, Lu Y, Sano T, Fang X, Tang P, Lapushin R, Koul D, Bookstein R, Stokoe D, Yung WKA, Mills GB and Steck PA (1998) MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58: 5285–5290
Davies MA, Koul D, Dhesi H, Berman R, Mcdonnell TJ, Mcconkey D, Yung WKA and Steck PA (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59: 2551–2556
Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LWK and Frierson HF Jr (1998) PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17: 1979–1982
Frisch SM and Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619–626
Frisch SM and Ruoslahti E (1997) Integrins and anoikis. Curr Opin Cell Biol 9: 701–706
Furnari FB, Lin H, Huang HJS and Cavenee WK (1997) Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 94: 12479–12484
Furnari FB, Huang H-JS and Cavanee WK (1988) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58: 5002–5008
Georgescu M-M, Kirsch KH, Akagi T, Shishido T and Hanafusa H (1999) The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96: 10182–10187
Gray IC, Phillips SMA, Lee SJ, Neoptolemos JP, Weissenbach J and Spurr NK (1995) Loss of the chromosomal region 10q23–25 in prostate cancer. Cancer Res 55: 4800–4803
Gray IC, Stewart LMD, Phillips SMA, Hamilton JA, Gray NE, Watson GJ, Spurr NK and Snary D (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78: 1296–1300
Guldberg P, Straten PT, Birck A, Ahrenkiel V, Kirkin AF and Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660–3663
Ittmann M (1996) Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 56: 2143–2147
Latil A and Lidereau R (1998) Genetic aspects of prostate cancer. Virchows Archiv an International Journal of Pathology 432: 389–406
Lee J-O, Yang H, Georgescu M-M, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P and Pavletich NP (1999) Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99: 323–334
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, Mccombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947
Macintosh CA, Stower M, Reid N and Maitland NJ (1998) Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 58: 23–28
Maehama T and Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid seond messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375–13378
Maier D, Jones G, Li XW, Schönthal AH, Gratzl O, Van Meir EG and Merlo A (1999) The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 59: 5479–5482
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R and Tonks NK (1997) P-TEN, the tumor supressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052–9057
Myers MP, Pass I, Batty IH, Van Der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP and Tonks NK (1998) The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513–13518
Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C and Lidereau R (1998) PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16: 2879–2883
Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM and Sellers WR (1999) Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 2110–2115
Rees S, Coote J, Stables J, Goodson S, Harris S and Lee MG (1996) Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. BioTechniques 20: 102–110
Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI and Boyd J (1997) Mutational analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657–3659
Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF and Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15: 356–362
Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB and Bova GS (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58: 204–209
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R and Yamada KM (1998) Inhibition of cell migration, spreading and focal adhesions by tumor suppressor PTEN. Science 280: 1614–1617
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935–3940
Trybus TM, Burgess AC, Wojno KJ, Glover TW and Macoska JA (1996) Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 56: 2263–2267
Vermes I, Haanen C, Steffensnakken H and Reutelingsperger C (1995) A novel assay for apoptosis – flow cytomeric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labeled annexin-V. J Immunol Methods 184: 39–51
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sharrard, R., Maitland, N. Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer 83, 1102–1109 (2000). https://doi.org/10.1054/bjoc.2000.1400
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1400